Prescription drug · ANDA
Azithromycin NDC 63187-093
Azithromycin monohydrate 200 mg/5mL · Powder, For suspension · Oral · Proficient Rx LP
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 63187-093-15 | 63187009315 | 15 mL in 1 BOTTLE (63187-093-15)Marketed from Jul 1, 2014 | |
| 63187-093-22 | 63187009322 | 22.5 mL in 1 BOTTLE (63187-093-22)Marketed from Apr 3, 2024 | |
| 63187-093-30 | 63187009330 | 30 mL in 1 BOTTLE (63187-093-30)Marketed from Jul 1, 2014 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Azithromycin
- Generic name (nonproprietary)
- azithromycin
- Active ingredients
- Azithromycin monohydrate — 200 mg/5mL
- Dosage form
- Powder, For suspension
- Route
- Oral
- Labeler
- Proficient Rx LP
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 065246
- Marketing start
- Listing expires
- Other FDA classes
- Macrolides (Chemical structure)
- Identifiers
- Product ID 63187-093_9d10dacc-ad17-48ec-b037-94987b2c40bcSPL ID 9d10dacc-ad17-48ec-b037-94987b2c40bcSPL set ID 44134421-cb0b-4e85-a3c8-d58bdb476fadRxCUI 141963UNII JTE4MNN1MDUPC 0363187093150
- Pharmacologic class
- Macrolide Antimicrobial
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N463187009315followed by a unit qualifier and the quantityPackage 63187-0093-15. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective . This label includes a boxed warning.
Indications (excerpt from the label)
INDICATIONS AND USAGE Azithromycin for oral suspension USP is indicated for the treatment of patients with mild to moderate infections (pneumonia: see WARNINGS ) caused by susceptible strains of the designated microorganisms in the specific conditions listed below. As recommended dosages, durations of therapy and applicable patient populations vary among these infections, please see DOSAGE AND ADMINISTRATION for specific dosing recommendations. Adults Acute bacterial exacerbations of chronic obstructive pulmonary disease due to Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae. Acute bacterial sinusitis due to Haemophilus influenzae, Moraxella catarrhalis or Streptoco…
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 065246
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Azithromycin | Azithromycin dihydrate 100 mg/5mL | Powder, For suspensionOral | A-S Medication Solutions | 50090-1868 |
| Azithromycin | Azithromycin monohydrate 200 mg/5mL | Powder, For suspensionOral | Teva Pharmaceuticals USA, Inc. | 0093-2026 |
| Azithromycin | Azithromycin monohydrate 100 mg/5mL | Powder, For suspensionOral | Teva Pharmaceuticals USA, Inc. | 0093-2027 |
| Azithromycin | Azithromycin monohydrate 100 mg/5mL | Powder, For suspensionOral | Preferred Pharmaceuticals Inc. | 68788-8675 |
| Azithromycin | Azithromycin monohydrate 100 mg/5mL | Powder, For suspensionOral | STATE HEALTH SERVICES, TEXAS DEPARTMENT OF | 55695-002 |
| Azithromycin | Azithromycin monohydrate 200 mg/5mL | Powder, For suspensionOral | STATE HEALTH SERVICES, TEXAS DEPARTMENT OF | 55695-003 |
| Azithromycin | Azithromycin monohydrate 100 mg/5mL | Powder, For suspensionOral | NuCare Pharmaceuticals,Inc. | 68071-1527 |